Net Trade Sales of CARVYKTI: Approximately $286 million, an 87.6% increase year-over-year and a 53.2% increase ...

Turning to our highlights. In the third quarter, we are pleased that CARVYKTI cells continued their strong momentum, ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

The study – which tested Carvykti in patients with one to three lines of prior therapy – gives J&J an opportunity to leapfrog Bristol-Myers Squibb and 2Seventy bio's rival BCMA CAR-T therapy ...

Johnson & Johnson has reported data from the Phase III CARTITUDE-4 clinical trial where CARVYKTI (ciltacabtagene autoleucel), ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Announced plans for new, state-of-the-art cell therapy R&D facility in Philadelphia Cash and cash equivalents, and time ...

In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI ®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of ...